Multiple myeloma: patient outcomes in real-world practice

Area of Science:

• Oncology
• Hematology
• Real-world evidence

Background:

• Multiple myeloma treatment landscape is evolving with numerous therapeutic options.
• Understanding patient journeys is crucial for optimizing care.
• Real-world data provides insights into clinical practice patterns.

Purpose of the Study:

• To investigate patient characteristics, treatment durations, outcomes, and symptom burden in multiple myeloma across Europe.
• To analyze the impact of increasing lines of therapy on treatment efficacy and patient experience.
• To provide insights into real-world clinical decisions and patient outcomes.

Main Methods:

• Retrospective chart review of 4997 patients with multiple myeloma across seven European countries.
• Data collected from 435 physicians on patient profiles, treatment lines, durations, responses, and toxicities.
• Analysis of treatment-free intervals and time to progression across therapy lines.

Main Results:

• Bone pain was the most common initial symptom. Median first-line therapy duration was 6 months, decreasing with subsequent lines.
• Treatment-free intervals and time to progression also decreased with more lines of therapy.
• Response depth declined significantly with each line (74% very good partial response at first line vs. 11% at fifth line).
• Toxicities and comorbidities increased in later lines, often leading to treatment discontinuation.

Conclusions:

• Real-world data highlight a decline in treatment effectiveness and an increase in toxicity with successive lines of multiple myeloma therapy.
• Physician-judged response depth correlates with time to progression, emphasizing the need for effective early-line treatments.
• These findings inform clinical practice and highlight challenges in managing advanced multiple myeloma.